Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The number of obese people will reach 50% of the world population by 2035. Obesity is a
chronic disease. For obese patients, dosage regimens have been determined for patients with a
"normal" BMI between 20-30 kg/m2. Based on plasma and urine concentrations, a pharmacokinetic
model will be performed to study in healthy volunteers, the predictive character of lean
mass, measured by DEXA, on renal elimination and therefore on acyclovir exposure. The main
objective of this study is to evaluate, in 4 volunteers groups representative of (1)
non-obese (18-24.9 kg/m2), (2) overweight (25-29.9 kg/m2), (3) grade 1 obesity (30-34.9
kg/m2) and (4) grade 2 obesity (35-39.9 kg/m2), the predictive nature of lean mass, measured
by DEXA, on renal elimination and therefore on acyclovir exposure.